- Home » News and EventsPage 18
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate
Jun 15, 2020
Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.
Catalent Partners with Spicona to Develop COVID-19 Vaccine Candidate Using GPEx® Cell Line Development Platform
Jun 10, 2020
Catalent today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19 at its Madison, Wisconsin facility.
Catalent’s Chair and CEO, John Chiminski, to Speak About R&D Leadership Through the Pandemic During BIO Digital
Jun 4, 2020
Catalent today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 – 12, 2020.
Statement from John Chiminski, Chair & CEO, on Recent Events in the U.S.
Jun 3, 2020
Catalent will continue to put our hearts into making our communities better through our programs promoting diversity & inclusion and corporate responsibility.
Catalent Appoints Charles Lickfold as Chief Information Officer
Jun 2, 2020
Catalent today announced the appointment of Charles Lickfold as Senior Vice President, Chief Information Officer. Mr. Lickfold succeeds John McGill, who plans to retire in September 2020.
Catalent Announces Acquisition of Japanese Facility to Provide Local and Global Clinical Supply Solutions
May 21, 2020
Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.
Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
May 20, 2020
Catalent today announced that Jean-François Chaubard, Senior Director, Open Innovation at Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference.
Triphase Accelerator and Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Non-Hodgkin’s Lymphoma
May 18, 2020
Triphase Accelerator and Catalent today announced interim results for Triphase Accelerator’s multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma.
Proactive Strategies to Avoid Supply Delays to be Presented by Catalent at Outsourcing in Clinical Trials Virtual Conference
May 14, 2020
Catalent today announced that it will present at the upcoming conference, ‘Outsourcing in Clinical Trials 2020 – A Virtual Experience’.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.